Literature DB >> 9825248

[Lithium in the treatment of acute depression].

M Adli1, T Bschor, B Canata, S Döpfmer, M Bauer.   

Abstract

In contrast to its widespread use in the prophylaxis of affective illness and in the acute treatment of mania lithium has not well been established in the treatment of acute depressive disorders. However, recent results from placebo controlled trials on lithium augmentation have shown its efficacy in the treatment of depressive disorders. Three different modes of application of lithium have been investigated since the 1960s and are reviewed in this article: 1. Although not a first line antidepressant lithium can be applied in monotherapy in the treatment of mild depressive episodes particularly in bipolar patients. 2. The successful additional use of lithium in patients not responding to conventional antidepressive treatment (lithium augmentation) has repeatedly been shown in controlled clinical trials since the 1980s. Therefore, lithium augmentation therapy has been established as treatment option of first choice in refractory depression. 3. Up to now there is little data concerning the initial combination of lithium with a conventional antidepressive drug: this indication of lithium seems to be useful in the treatment of depressive episodes in bipolar patients with a history of switching into mania during administration of tricyclics and leading to faster symptom relief.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9825248     DOI: 10.1055/s-2007-995282

Source DB:  PubMed          Journal:  Fortschr Neurol Psychiatr        ISSN: 0720-4299            Impact factor:   0.752


  5 in total

Review 1.  Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review.

Authors:  Hans-Jürgen Möller; Heinz Grunze; Karl Broich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-08-04       Impact factor: 5.270

Review 2.  [Twenty-five years of lithium augmentation].

Authors:  T Bschor; U Lewitzka; A Pfennig; M Bauer
Journal:  Nervenarzt       Date:  2007-11       Impact factor: 1.214

Review 3.  Lithium in the treatment of major depressive disorder.

Authors:  Tom Bschor
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

Review 4.  Efficacy of Carbamazepine and Its Derivatives in the Treatment of Bipolar Disorder.

Authors:  Anna Grunze; Benedikt L Amann; Heinz Grunze
Journal:  Medicina (Kaunas)       Date:  2021-04-30       Impact factor: 2.430

5.  Lithium monotherapy increases ACTH and cortisol response in the DEX/CRH test in unipolar depressed subjects. A study with 30 treatment-naive patients.

Authors:  Tom Bschor; Dirk Ritter; Patricia Winkelmann; Sebastian Erbe; Manfred Uhr; Marcus Ising; Ute Lewitzka
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.